Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy

Jianhua Liu,Zhongmin Li,Duoyi Zhao,Xiangru Feng,Chunxi Wang,Di Li,Jianxun Ding

DOI: https://doi.org/10.1016/j.matdes.2021.109465

2021-04-01

Abstract:<p>Chemotherapeutic nanoformulations, which can induce the immunogenic death of tumor cells, have attracted increasing attention for their abilities to enable and potentiate combination chemoimmunotherapy. Immunogenic cell death (ICD) causes the release of tumor-associated antigens, tumor-specific antigens, danger-associated molecular patterns, and pro-inflammatory cytokines, which trigger adaptive immune cells to elicit an antitumor immune response. The combination of ICD-inducing nanomedicines and immunoactivators represents a promising strategy for enhancing chemoimmunotherapy in clinical applications. In this review, we provide an overview of the latest advances in chemotherapeutic nanoformulation-mediated immune activation and the combination strategies with various immunoactivating agents, such as immune checkpoint inhibitors, indoleamine 2,3-dioxygenase inhibitors, cytokines, and Toll-like receptor agonists, and predict their potential to contribute significantly to clinical cancer chemoimmunotherapy.</p>

materials science, multidisciplinary

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to induce immunogenic death (ICD) of tumor cells by designing and applying chemotherapeutic nano - formulations, thereby enhancing the effect of combined chemo - immunotherapy. Specifically, the paper explores how to combine chemotherapeutic nano - formulations capable of inducing ICD with various immune activators (such as immune checkpoint inhibitors, indoleamine 2,3 - dioxygenase inhibitors, cytokines and Toll - like receptor agonists) to improve the clinical efficacy of cancer treatment. The paper emphasizes the potential of these combination strategies in overcoming tumor immune escape, promoting anti - tumor immune responses and improving patient prognosis.

The key points mentioned in the paper include:
- **Immunogenic cell death (ICD)** : Chemotherapeutic nano - formulations can induce tumor cells to undergo ICD, leading to the release of tumor - associated antigens and danger - associated molecular patterns, triggering anti - tumor immune responses in adaptive immune cells.
- **Immune checkpoint inhibitors** : When used in combination with ICD inducers, they can further enhance anti - tumor immune responses, such as PD - 1/PD - L1 inhibitors and CTLA - 4 inhibitors.
- **Indoleamine 2,3 - dioxygenase (IDO) inhibitors** : By inhibiting IDO activity, they reduce T - cell suppression and the number of Treg cells, thereby amplifying the immune activation caused by ICD.
- **Nanomaterial design** : By designing nanomaterials with specific functions, such as pH - responsive nanoparticles, photosensitizer - loaded nanoparticles, etc., precise drug release and targeted delivery are achieved, improving the treatment effect.

In conclusion, this paper aims to develop more effective cancer treatment strategies, especially in combined chemo - immunotherapy, through the comprehensive use of chemotherapeutic nano - formulations and immune activators.